Featured journal covers

Featured edited books

Publications and editorials

  1. M Hong and G Bitan (2024) Recent advances and future therapy development for Alzheimer’s disease and related disorders. Neural Regener. Res., 19: 1877-1878.
  2. C Lantz, J Lopez, AK Goring, MA Zenaidee, KE Biggs, JP Whitelegge, RR Ogorzalek Loo, F-G Klärner, T Schrader, G Bitan, and JA Loo (2023) Characterization of Molecular Tweezer Binding on α-Synuclein with Native Top-Down Mass Spectrometry and Ion Mobility-Mass Spectrometry Reveals a Mechanism for Aggregation Inhibition. J. Am. Soc. Mass Spectrom., 34: 2739-2747.
  3. HB Taha, E Chawla, and G Bitan (2023) IM-MS and ECD-MS/MS Provide Insight into Modulation of Amyloid Proteins Self-Assembly by Peptides and Small Molecules. J. Am. Soc. Mass Spectrom., 34: 2066-2086.
  4. S Dutta, S Hornung, HB Taha, and G Bitan (2023) Biomarkers for parkinsonian disorders in CNS-originating EVs – promise and challenges. Acta Neuropathol., 145: 515-540.
  5. HB Taha, S Hornung, S Dutta, L Fenwick, O Lahgui, K Howe, N Elabed, I Del Rosario, DY Wong, A Duarte Folle, D Markovic, J-A Palma, UJ Kang, RN Alcalay, M Sklerov, H Kaufmann, BL Fogel, JM Bronstein, B Ritz, and G Bitan (2023) Toward a Biomarker Panel measured in CNS-originating Extracellular Vesicles for Improved Differential Diagnosis of Parkinson’s Disease and Multiple System Atrophy. Transl. Neurodegener., 12: 14.
  6. S Dutta*, S Hornung*, HB Taha*, K Biggs, I Siddique, LM Chamoun, H Shahpasand-Kroner, C Lantz, M Herrera-Vaquero, N Stefanova, JA Loo, and G Bitan (2023) Development of a Novel Electrochemiluminescence ELISA for Quantification of α‐Synuclein Phosphorylated at Ser129 in Biological Samples. ACS Chem. Neurosci., 14: 1238-1248. *Equal contribution.
  7. H Shahpasand-Kroner*, I Siddique*, R Malik, G Linares, MI Ivanova, J Ichida, T Weil, J Münch, E Sanchez-Garcia, F-G Klärner, T Schrader and G Bitan (2023) Molecular tweezers – supramolecular hosts with broad-spectrum biological applications. Pharmacol. Rev. 75: 263-308. *Equal contribution.
  8. KN Maina, C Smet-Nocca, and G Bitan (2023) Using FRET-Based Biosensor Cells to Study the Seeding Activity of Tau and α-Synuclein. Methods. Mol. Biol. 2551: 125-145.
  9. HB Taha, B Kearny, and G Bitan (2022) A minute fraction of a-synuclein in extracellular vesicles may be a major contributor to α-synuclein spreading following autophagy inhibition. Frontiers Mol. Neurosci., 15, DOI: doi.org/10.3389/fnmol.2022.1001382.
  10. JA Palma, J Martinez, P Millar Vernetti, T Ma, MA Perez, J Zhong, Y Qian, S Dutta, KN Maina, I Siddique, G Bitan, B Ades-Aron, TM Shepherd, UJ Kang, and H Kaufmann (2021) mTOR inhibition with sirolimus in multiple system atrophy: a randomized, double-blind, placebo-controlled futility trial and 1-year biomarker longitudinal analysis. Mov. Disord., 37: 778-789.
  11. H Shahpasand-Kroner, J Portillo, C Lantz, PM Seidler, N Sarafian, JA Loo, and G Bitan (2021) Three-repeat and four-repeat tau isoforms form different oligomers. Prot. Sci., 31: 613-627.
  12. Z Li, I Siddique, I Hadrović, A Kirupakaran, J. Li, Y. Zhang, F-G Klärner, T Schrader, and G Bitan (2021) Lysine-selective molecular tweezers are cell-penetrant a concentrate in lysosomes. Commun. Biol., 4: 1076.
  13. S Dutta, S Hornung, A Kruayatidee, KN Maina, I del Rosario, KC Paul, D Wong, A Duarte Folle, D Markovic, J-A Palma, GE Serrano, CH Adler, SL Perlman, WW Poon, UJ Kang, RN Alcalay, M Sklerov, KH Gylys, H Kaufmann, BL Fogel, JM Bronstein, B Ritz, and G Bitan (2021) α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson’s disease from multiple system atrophy. Acta Neuropathol., 142: 495-511. Read the UCLA press release, "New blood test reads messages from the brain."
  14. J Di*, I Siddique*, Z Li, G Malki, S Hornung, S Dutta, I Hurst, E Ishaaya, A Wang, S Tu, A Boghos, I Ericsson, F-G Klärner, T Schrader, and G Bitan (2021) The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alz. Res. Ther., 13: 6. *Equal contribution.
  15. N Bengoa-Vergniory, E Faggiani, P Ramos-Gonzalez, E Kirkiz, N Connor-Robson, LV Brown, I Siddique, Z Li, S Vingill, M Cioroch, F Cavaliere, S Threlfell, B Roberts, T Schrader, F-G Klärner, S Cragg, B Dehay, G Bitan, C Matute, E Bezard and R Wade-Martins (2020) CLR01 protects dopaminergic neurons in vitro and in vivo in human neurons and mouse models of Parkinson’s. Nat. Commun., 11: 4885.
  16. R Malik*, C Corrales*, M Linsenmeier, H Alalami, N Sepanj, and G Bitan (2020) Examination of SOD1 aggregation modulators and their potential toxicity in vitro. FASEB J. 34: 11957-11969. *Equal contribution.
  17. AJ Mason*, I Hurst*, R Malik, I Solomonov, I Sagi, F-G Klärner, T Schrader, and G Bitan (2020) Different inhibitors of Aβ42-induced toxicity have distinct metal-ion dependency. ACS Chem. Neurosci. 11: 2243–2255. *Equal contribution.
  18. S Hornung, S Dutta, and G Bitan (2020) Brain-derived blood exosomes as a promising source of biomarkers: opportunities and challenges. Frontiers Mol. Neurosci., 13: 38.
  19. G Bitan (2019) Disease-modifying therapy for proteinopathies—can the exception become the rule? In: Progress in Molecular Biology and Translational Science, Molecular Biology of Neurodegenerative Diseases: Visions for the Future. D. Teplow Ed. Elsevier/Academic Press. Pp. 277-287.
  20. WS Shin, J Di, Q Cao, B Li, PM Seidler, KA Murray, G Bitan, and L Jiang (2019) Amyloid β-protein oligomer promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alz Res. Ther., 11: 86.
  21. EY Hayden, J Putman, S Nunez, WS Shin, M Oberoi, M Charreton, S Dutta, Z Li, Y Komuro, MT Joy, G Bitan, A MacKenzie-Graham, L Jiang, and JD Hinman (2019) Ischemic axonal injury up-regulates MARK4 in cortical neurons and primes tau phosphorylation and aggregation. Acta Neuropathol. Commun. 7: 135.
  22. M Herrera-Vaquero†, D Bouquio†, M Kallab, K Biggs, G Nair, J Ochoa, W Poewe, GK Wenning, F-G Klärner, T Schrader, G Bitan*, and N Stefanova* (2019) The molecular tweezer CLR01 ameliorates the pathological phenotype in a transgenic model of multiple system atrophy. BBA-Mol. Basis Dis. 1865: 165513. †Equal contribution. *Co-corresponding authors.
  23. C Despres†, J Di†, F-X Cantrelle, Z Li, I Huvent, B Chambraud, J Zhao, J Chen, S Chen, G Lippens, F Zhang, R Linhardt, C Wang, F-G Klärner, T Schrader, I Landrieu, G Bitan*, and C Smet-Nocca* (2019) Major differences between the self-assembly and seeding behavior of heparin-induced- and in-vitro-phosphorylated tau and their modulation by potential inhibitors. ACS Chem. Biol. 14: 1363-1379.  †Equal contribution. *Co-corresponding authors.
  24. Z Yan†, S Dutta†, Z Liu, X Yu, N Mesgarzadeh, F Ji, G Bitan* and Y-H Xie* (2019) A Label-free Platform for Unambiguous Cell-specific Identification of Exosomes. ACS Sensors, 4: 488-497. †Equal contribution. *Co-corresponding authors.
  25. R Malik, H Meng, P Wongkongkathep, CI Corrales, N Sepanj, SR Atlasi, F-G Klärner, T Schrader, MJ Spencer. JA Loo, M Wiedau-Pazos, and G Bitan (2019) The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. J. Biol. Chem., 294:  3501-3513.
  26. RS Atlasi, R Malik, CI Corrales, L Tzeplaeff, J Whitelegge, N Cashman, and G Bitan (2018) Investigation of anti-SOD1 antibodies yields new structural insight into SOD1 misfolding and surprising behavior of the antibodies themselves. ACS Chem. Biol., 13: 2794–2807.
  27. EY Hayden, JL Conovaloff, A Mason, G Bitan, and DB Teplow. Preparation of pure populations of amyloid β-protein oligomers of defined size (2018) Methods Mol. Biol., 1779: 3-12.
  28. R Malik, J Di, G Nair, A Attar, K Taylor, E Teng, F-G Klärner, T Schrader, and G Bitan (2018) Using molecular tweezers to remodel abnormal protein self-assembly and inhibit the toxicity of amyloidogenic proteins. Methods Mol. Biol. 1777: 369-386.
  29. F Richter, I Magen, P Lee, S Subramaniam, J Hayes, A Attar, C Zhu, N Franich, N Bove, K De La Rosa, J Kwong, F-G Klärner, T Schrader, M- F Chesselet, and G Bitan (2017) A molecular tweezer ameliorates motor deficits in mice overexpressing α-synuclein. Neurotherapeutics, 14: 1107-1119. Read the UCLA press release, "Balance and movement improved in animal model of Parkinson’s disease."
  30. EY Hayden, JL Conovaloff, A Mason, G Bitan, and DB Teplow (2016) Preparation of pure populations of covalently stabilized amyloid β-protein oligomers of specific sizes. Anal. Biochem., 518: 78-85.
  31. T Schrader, G Bitan, and F-G Klärner (2016) Molecular Tweezers for Lysine and Arginine – Powerful Inhibitors of Pathologic Protein Aggregation. Chem. Commun. 52: 11309-11317.
  32. H Li, F Rahimi, and G Bitan (2016) Modulation of amyloid β-protein (Aβ) assembly by homologous C-terminal fragments as a strategy for inhibiting Aβ toxicity. ACS Chem. Neurosci. 7: 845-856.
  33. A Lulla, L Barnhill, G Bitan, M Ivanova, B Nguyen, K O’Donnel, M Stahl, C Yamashiro, F-G Klärner, T Schrader, A Sagasti, and JM Bronstein (2016) Neurotoxicity of the Parkinson’s Disease-Associated Pesticide Ziram is Synuclein-Dependent in Zebrafish Embryos, Environ. Health Perspect., 124: 1766-1775. Read the UCLA press release, "UCLA scientists discover protective strategy against pesticide-linked Parkinson’s disease."
  34. F Rahimi, H Li, S Sinha, and G Bitan (2016) Modulators of Amyloid β-Protein (Aβ) Self-Assembly. In: Developing Therapeutics for Alzheimer’s Disease: Progress and Challenges, Wolfe, M.S. Ed. Elsevier/Academic Press. Pp. 97-191.
  35. SM Fogerson, AJ van Brummen, DJ Busch, SR Allen, R Roychaudhuri, SM Banks, F-G Klärner, T Schrader, G Bitan, and JR Morgan (2016) Reducing synuclein accumulation improves neuronal survival after spinal cord injury, Exp. Neurol. 278: 105-115.
  36. X Zheng, C Wu, D Liu, H Li, G Bitan, J-E Shea and MT Bowers (2015) Mechanism of C-Terminal Fragments of Amyloid β-Protein as Aβ Inhibitors: C-Terminal Interactions Play a Key Role in Their Inhibitory Activity, J. Phys. Chem. B, 119: 4831-41.
  37. R Roychaudhuri, X Zheng, A Lomakin, P Maiti, MM Condron, GB Benedek, G Bitan, MT Bowers, and DB Teplow (2015) Role of species-specific primary structure differences in Aβ42 assembly and neurotoxicity, ACS Chem. Neurosci. 6: 1941-1955.
  38. R Malishev, S Nandi, S Kolusheva, Y Levi-Kalisman, F-G Klärner, T Schrader, G Bitan*, and R Jelinek* (2015) Toxicity inhibitors protect lipid membranes from disruption by Aβ42, ACS Chem. Neurosci., 6: 1860-1869. *Co-corresponding authors.
  39. E Lump, LM Castellano, C Meier, J Seeliger, N Erwin, B Sperlich, CM Stürzel, S Usmani, RM Hammond, J von Einem, G Gerold, F Kreppel, K Bravo-Rodriguez, T Pietschmann, VM Holmes, D Palesch, O Zirafi, D Weissman, A Sowislok, B Wettig, C Heid, F Kirchhoff, T Weil, F-G Klärner, T Schrader, G Bitan, E Sanchez-Garcia, R Winter, J Shorter, and J Münch (2015) A molecular tweezer antagonizes seminal amyloids and HIV infection, eLife, 2015; 4: e05397. Read the Penn Medicine press release, "Targeting HIV in Semen to Shut Down AIDS."
  40. G Herzog, MD Shmueli, L Levi, L Engel, E Gazit, F-G Klärner, T Schrader, G Bitan, and D Segal (2015) The Lys-specific molecular tweezer, CLR01, modulates aggregation of mutant p53 DNA binding domain and inhibits its toxicity, Biochemistry, 54: 3729–3738. Featured in Chemical Research in Toxicology – Spotlight.
  41. DHJ Lopes, A Attar, G Nair, EY Hayden, Z Du, K McDaniel, S Dutt, K Bravo-Rodriguez, S Mittal, F-G Klärner, C Wang, E Sanchez-Garcia, T Schrader, and G Bitan (2015) Molecular tweezers inhibit islet amyloid polypeptide assembly and toxicity by a new mechanism, ACS Chem., 10: 1555-1569.
  42. X Zheng, D-Y Liu, F-G Klärner, T Schrader, G Bitan, and MT Bowers (2015) Amyloid β-protein Assembly: The Effect of Molecular Tweezer CLR01 and CLR03. J. Phys. Chem. B, 119: 4831-4841. ACS Editor’s Choice.
  43. A Attar, D Meral, B Urbanc, and G Bitan (2014) Assembly of amyloid β-protein variants containing familial Alzheimer’s disease-linked amino acid substitutions. In: Bionanoimaging: Protein Misfolding & Aggregation. V Uversky and Y Lyubchenko Eds. Elsevier/Academic Press. Pp. 429–442.
  44. N Ferreira, A Pereira-Henriques, A Attar, F-G Klärner, T Schrader, G Bitan, MJ Saraiva, and MR Almeida (2014) Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 11: 450-461.
  45. A Attar, W-TC Chan, F-G Klärner, T Schrader, and G Bitan (2014) Safety and pharmacological characterization of the molecular tweezer CLR01. BMC Pharm. Tox., 15: 23, doi:10.1186/2050-6511-15-23.
  46. A Attar and G Bitan (2014) Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “Molecular Tweezers” – from the Test Tube to Animal Models. Curr. Pharm. Des., 20: 2469-2483.
  47. S Acharya, B Safaie, P Wongkongkathep, MI Ivanova, A Attar, F-G Klärner, T Schrader, JM Loo, G Bitan, and LJ Lapidus (2014) Molecular Basis for Preventing α-synuclein Aggregation by a Molecular Tweezer. J. Biol. Chem., 289: 10727-10737. Read the Michigan State University press release, "MSU physicists push new Parkinson’s treatment toward clinical trials | MSUToday | Michigan State University."
  48. F Rahimi and G Bitan (2014) Methods for studying and structure–function relationships of non-fibrillar protein assemblies in Alzheimer’s disease and related disorders. In: Advances in Alzheimer Research. Vol. 2, DK Lahiri Ed. Bentham Scientific. Pp. 291-374.
  49. A Attar, T Liu, W-T C Chan, J Hayes, M Nejad, K Lei, and G Bitan (2013) A Shortened Barnes Maze Protocol Reveals Memory Deficits at 4-Months of Age in the Triple-Transgenic Mouse Model of Alzheimer’s Disease. PLoS ONE, 8: e80355, doi: 10.1371/journal.pone.0080355.
  50. CR Connors, DJ Rosenman, DHJ Lopes, S Mittal, G Bitan, A Garcia, and C Wang (2013) Tranilast Binds to Aβ Monomers and Promotes Aβ Fibrillation. Biochemistry, 52: 3995-4002.
  51. A Attar, F Rahimi and G Bitan (2013) Modulators of amyloid protein aggregation and toxicity: EGCG and CLR01. Translational Neurosci., 4: 385-409.
  52. C Ripoli, R Piacentini, E Riccardi, L Leone, G Bitan, and C Grassi (2013) Effects of different forms of amyloid β-protein in rodent hippocampal neurons and brain slices. Neurobiol. Aging, 34: 1032–1044.
  53. A Attar, C Ripoli, E Riccardi, P Maiti, DD Li Puma, T Liu, J Hayes, MR Jones, K Lichti-Kaiser, F Yang, GD Gale, C-H Tseng, M Tan, C-W Xie, JL Straudinger, F-G Klärner, T Schrader, SA Frautschy, C Grassi, and G Bitan (2012) Protection of primary neurons and mouse brain from Alzheimer’s pathology by molecular tweezers. Brain, 135: 3735-3748. Read the UCLA press release, "Researchers report potential new treatment to stop Alzheimer's disease | UCLA Health."
  54. S Sinha, DHJ Lopes, and G Bitan (2012) A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity. ACS Chem. Neurosci., 3: 473-481. “Most-read” paper in the 2nd quarter of 2012.
  55. S Sinha, Z Du, P Maiti, F-G Klärner, T Schrader, C Wang, and G Bitan (2012) Comparison of three amyloid assembly inhibitors – the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem. Neurosci., 3: 451-458.
  56. I Solomonov, E Korkotian, B Born, D Kaganovich, Y Feldman, A Bitler, AF Rahimi, H Li, G Bitan, and I Sagi (2012) Zn2+-Aβ complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons. J. Biol. Chem., 287: 20555-20564.
  57. JM Ringman, AT Fithian, K Gylys, JL Cummings, G Coppola, D Elashoff, D Pratico, J Moskovitz, and G Bitan (2012) Plasma methionine sulfoxide in persons with familial Alzheimer’s disease mutations. Dement. Geriatr. Cogn. Disord., 33: 219-225.
  58. S Prabhudesai, S Sinha, A Attar, A Kotagiri, AG Fitzmaurice, R Lakshmanan, MI Ivanova, JA Loo, F-G Klärner, T Schrader, G Bitan*, and J Bronstein* (2012) A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo. Neurotherapeutics, 9: 464-476. *Co-corresponding authors. “Most Widely Discussed Paper” on Springer’s “#NeuroStars!” Read the UCLA press release, "Parkinson's disease stopped in animal model | UCLA Health."
  59. P Novick, DHJ Lopes, K Branson, A Esteras-Chopo, IA Graef, G Bitan, and VS Pande (2012) Design of Aβ42 aggregation inhibitors from a predicted structural motif. J. Med. Chem., 55: 3002–3010.
  60. C Rosensweig, K Ono, K Murakami, DK Lowenstein, G Bitan, and DB Teplow. Preparation of stable amyloid β-protein oligomers of defined assembly order (2012) Methods Mol. Biol. 489: 23-31.
  61. DHJ Lopes, S Sinha, C Rosensweig, and G Bitan. Application of Photochemical Cross-linking to the Study of Oligomerization of Amyloidogenic Proteins (2012) Methods Mol. Biol. 489: 11-22.
  62. H Li, R Zemel, DHJ Lopes, BH Monien, and G Bitan (2012) A two-step strategy for SAR studies of N-methylated Aβ42 C-terminal fragments as Aβ42 toxicity inhibitors. ChemMedChem, 7: 515-522.
  63. F Rahimi and G Bitan (2012) The structure and function of fibrillar and oligomeric assemblies of amyloidogenic proteins. In: Pre-fibrillar amyloidogenic protein assemblies—common cytotoxins underlying degenerative diseases. F Rahimi and G Bitan, Eds. Springer Science+Media B.V., Dordrecht. pp. 1-36.
  64. T Liu and G Bitan (2012) Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases — strategies and mechanisms. ChemMedChem, 7: 359-374.
  65. MM Gessel, C Wu, H Li, G Bitan, J-E Shea, and MT Bowers (2012) Aβ(39-42) Modulates Aβ Oligomerization but not Fibril Formation. Biochemistry, 51: 108-117.
  66. H Li, Z Du, DHJ Lopes, EA Fradinger, C Wang, and G Bitan. C-terminal Tetrapeptides Inhibit Aβ42-induced Neurotoxicity Primarily Through Specific Interaction at the N-terminus of Aβ42. (2011) J. Med. Chem., 54: 8451-8460.
  67. J Moskovitz, P Maiti, DHJ Lopes, DB Oien, A Attar, T Liu, S Mittal, J Hayes, and G Bitan (2011) Induction of methionine-sulfoxide reductases protects neurons from amyloid β-protein insults in vitro and in vivo. Biochemistry, 50: 10687–10697.
  68. S Sinha, DHJ Lopes, Z Du, ES Pang, A Shanmugam, A Lomakin, P Talbiersky, A Tennstaedt, K McDaniel, R Bakshi, P-Y Kuo, M Ehrmann, GB Benedek, JA Loo, F-G Klärner, T Schrader, C Wang, G Bitan (2011) Lysine-specific molecular tweezers are broad-spectrum inhibitor of aggregation and toxicity of amyloid proteins. J. Am. Chem. Soc., 133: 16958–16969. Featured in Chemical & Engineering News.
  69. B Urbanc, M Bentel, L Cruz, H Li, EA Fradinger BH Monien, and G Bitan (2011) In silico study of Aβ1−42 oligomer formation in the presence of Aβ-derived toxicity inhibitors. J. Mol. Biol., 410: 316–328.
  70. K Hochdörffer, J März-Berberich, L Nagel-Steger, M Epple, W Meyer-Zaika, A Horn, H Sticht, S Sinha, G Bitan, and T Schrader (2011) Rational Design of β-Sheet Ligands against Aβ42-induced toxicity. J. Am. Chem. Soc., 133: 4348–4358.
  71. P Maiti, R Piacentini, C Ripoli, C Grassi, and G Bitan (2010) Surprising assembly and toxicity behavior of amyloid β-protein oxidized to sulfone. Biochem. J., 433: 323-332.
  72. H Li, BH Monien, A Lomakin, R Zemel, EA Fradinger, M Tan, SM Spring, B Urbanc, C-W Xie, GB Benedek, and G Bitan (2010) Mechanistic Investigation of the Inhibition of Aβ42 Assembly and Neurotoxicity by Aβ42 C-terminal Fragments. Biochemistry, 49: 6358-6364.
  73. F Rahimi and G Bitan (2010) Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer’s Disease, J. Vis. Exp. 39, doi: 10.3791/1955.
  74. P Maiti, A Lomakin, GB Benedek and G Bitan (2010) Despite its role in assembly, methionine 35 is not necessary for amyloid β-protein toxicity. J. Neurochem. 113: 1252-1262.
  75. H Li, BH Monien, EA Fradinger, B Urbanc and G Bitan (2010) Biophysical Characterization of Aβ42 C-terminal Fragments—Inhibitors of Aβ42 Neurotoxicity. Biochemistry, 49: 1259-1267.
  76. F Rahimi, K Murakami, JL Summers, C-HB Chen and G Bitan (2009) RNA aptamers generated against oligomeric Aβ40 recognize common amyloid aptatopes with high sensitivity. PLoS ONE, 4, e7694. doi:10.1371/journal.pone.0007694.
  77. SL Bernstein, NF Dupuis, ND Lazo, T Wyttenbach, MM Condron, G Bitan, DB Teplow, J-E Shea, BT. Ruotolo, CV. Robinson, and MT Bowers (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer’s disease. Nat. Chem. 1: 326-331.
  78. C Wu, SL Bernstein, M Murray, MM Condron, G Bitan, MT Bowers, and J-E Shea (2009) Structural characterization of Amyloid β-protein C-terminal fragments. J. Mol. Biol., 387: 492-501.
  79. H Li, F Rahimi, K Murakami, P Maiti, S Sinha, and G Bitan (2009) Amyloids and protein aggregation –analytical methods. In Encyclopedia of Analytical Chemistry, S1-S3, RA Meyers, Ed. Chichester, UK, John Wiley & Sons Ltd., pp. 635-666.
  80. F Rahimi, P Maiti, and G Bitan (2009) Photo-Induced Cross-Linking of Unmodified Proteins (PICUP) Applied to Amyloidogenic Peptides. J. Vis. Exp., 23, doi: 10.3791/1071.
  81. F Rahimi, A Shuanmugam, and G Bitan (2008) Structure–Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimer’s Disease and Related Disorders. Curr. Alz. Res. 5: 319-341.
  82. EA Fradinger, BH Monien, B Urbanc, A Lomakin, M Tan, H Li, SM Spring, MM Condron, L Cruz, C-W Xie, GB Benedek, and G Bitan (2008) C-terminal peptides co-assemble into Aβ42 oligomers and protect neurons against Aβ42-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 105: 14175–14180.
  83. MM Condron, BH Monien, and G Bitan (2008) Synthesis and purification of highly hydrophobic peptides derived from the C-terminus of amyloid β-protein. Open Biotechnol, J., 2: 87-93.
  84. A Shanmugam, BH Monien, and G Bitan (2008) Development in Diagnostic and Therapeutic Strategies for Alzheimer’s Disease. In: Sun M-K, Ed. Research Progress in Alzheimer’s Disease and Dementia. Vol. 3. Nova Science Publisher, Inc. pp. 193-250.
  85. G Bitan (2006) Structural study of metastable amyloidogenic protein oligomers by Photo-Induced Cross-linking of Unmodified Proteins (PICUP). Methods Enzymol. 413: 217-236.
  86. BH Monien, LG Apostolova, and G Bitan (2006) Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there? Expert Rev. Neurotherapeutics. 6: 1293-1306.
  87. EA Fradinger and G Bitan (2005) En route to early diagnosis of Alzheimer’s disease – are we there yet? Trends Biotech., 23: 531-533.
  1. G Bitan (2020) The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies? Ann. Trans Med., 8(11):719. doi: 10.21037/atm.2020.01.117.
  2. Thor Benson (2015) Researchers in Australia Announce Alzheimer’s Breakthrough. ATTN: December 27th, 2015.
  3.  Madolyn Bowman Rogers (2015) Enter Aη: Alternative APP Cleavage Creates Synaptotoxic PeptideAlzheimer Research Forum August 31st, 2015.
  4. Madolyn Bowman Rogers (2015) Do Extended Species of Aβ Poison Synapses, Masquerade As Dimers? Alzheimer Research Forum May 2nd, 2015.
  5. G Bitan (2014) Clear the way to healthy ageing. UCLOUD.
  6. Hamish McDougal (2013) Prana’s PBT2 may clear amyloid-beta for Phase II Alzheimer’s success though relevance questioned – experts. BioPharm Insight, December 2013. Link to the article is no longer available.
  7. Hamish McDougal (2013) Pfizer’s ACC-001, Transition’s ELND005 face Phase II safety and efficacy hurdles in Alzheimer’s – neurologists. BioPharm Insight, December 2013. Link to the article is no longer available.
  8. G Bitan (2013) Invited commentary by Alzforum on paper of the week by Watt et al., in Acta Neuropathol. (Jan. 25th 2013) Oligomers, fact or artifact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Feb 14th, 2013.
  9. Arielle Duhaime-Ross (2013) Discovery of distinct peptides in brains of Alzheimer’s patients could help diagnosis. Nature blog Sep 12th, 2013.
  10. G Bitan (2012) Can We Accelerate the Path towards Therapy for Amyloid-Related Diseases? J. Gerontol. Geriatr. Res. 1: e106. doi:10.4172/jggr.1000e106.
  11. A Attar, G Bitan, and H Li (2010) Invited commentary by Alzforum on paper of the week by Ladiwala et al., in J. Biol. Chem. (Nov. 23rd 2010) Aromatic small molecules remodel toxic soluble oligomers of amyloid β through three independent pathways. Dec 29th, 2010. Link to the article is no longer available.
  12. E Landhuis (2010) Flexible N-Termini Key to Aβ42 Oligomer Toxicity? Alzheimer Research Forum Dec 14th, 2010.
  13. E Landhuis (2010) Tau Oligomer Antibodies Relieve Motor Deficits in Mice. Alzheimer Research Forum Nov 25th, 2010.
  14. W Wolfson (2008) Unraveling the Tangled Brain of Alzheimer’s. Chemistry & Biology Innovations 15: 89-90.
  15. L Carol (2006) Scientists focus on precursors to amyloid plaque in Alzheimer disease. Neurology Today 6: 20.